Biotechnology company focused on developing therapies for autoimmune diseases and chronic inflammatory conditions.
ZimVie Inc. is a dynamic medical technology company specializing in the development, manufacturing, and global distribution of innovative products and solutions aimed at treating diverse spine pathologies and enhancing dental tooth replacement and restoration procedures. The company's extensive product portfolio includes advanced dental implant systems, prosthetic components, and surgical instrumentation, along with a comprehensive range of bone grafts, barrier membranes, allografts, and collagen-based wound care products.
In addition to its dental offerings, ZimVie Inc. provides cutting-edge intraoral scanners, virtual treatment planning services, guided surgery solutions, and CAD/CAM workflow systems. These technologies are complemented by patient-specific restorative components and intra-oral scanners, ensuring precision and efficacy in dental procedures. Moreover, the company excels in spinal care innovations, offering spinal fusion implants, instrumentation for various spinal procedures, biologics, and advanced bone healing technologies.
ZimVie Inc. distinguishes itself through its commitment to minimally invasive surgery (MIS) solutions, including Vital MIS and Timberline, which prioritize patient outcomes and recovery. The company also contributes to motion preservation advancements with products like Mobi-C and The Tether, aimed at preserving spinal function and mobility. Founded in 2021 and headquartered in Westminster, Colorado, ZimVie Inc. embodies a forward-looking approach to medical technology, leveraging state-of-the-art research and development to address critical healthcare needs worldwide.
With a focus on innovation and excellence, ZimVie Inc. continues to redefine standards in both dental and spinal care domains. By integrating advanced technologies with a dedication to quality and patient care, the company strives to empower healthcare professionals and improve outcomes for patients globally.